Premium
Evaluation of NovoRapid infusion as a treatment option in the management of diabetic ketoacidosis
Author(s) -
Kwok Raylene,
SztalMazer Shoshana,
Hopkins Ria E.,
Poole Susan G.,
Grannell Louise,
Coutsouvelis John,
Topliss Duncan J.
Publication year - 2017
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.13607
Subject(s) - medicine , insulin aspart , diabetic ketoacidosis , ketoacidosis , insulin , human insulin , diabetes mellitus , retrospective cohort study , type 1 diabetes , intensive care medicine , anesthesia , endocrinology
This study evaluates the clinical efficacy and safety of NovoRapid (insulin aspart) compared to Actrapid™ (human neutral insulin) for diabetic ketoacidosis ( DKA ). In this retrospective study involving 40 patients, no statistically significant differences were observed between biochemical variables, infusion duration or complications in patients treated with insulin aspart or human neutral insulin. These results support the use of insulin aspart as an effective and safe alternative to human neutral insulin in DKA .